The loss of expression of particular microRNAs can contribute to tumorigenesis. Kota et al. (2009) now explore in a mouse model a promising new approach for the treatment of liver cancerre-establishing the expression of an miRNA using a viral vector.
Notch activation. These observations in cultured cells are relevant in vivo, as residual levels of Dll4 that could potentially suppress angiogenesis are present in stalk cells. By antagonizing these signals, Jag1 can promote stalk cell activation and maintain the VEGF response. Supporting evidence for Fringe-mediated regulation of angiogenesis also comes from genetic deletion of another Fringe family member, Lunatic Fringe, in mice. Loss of Lunatic Fringe results in enhanced retinal angiogenesis and increased tip cell numbers, indicating reduced Notch activation.
In addition to antagonizing Dll4-mediated activation of Notch signaling, Jag1 could also promote angiogenesis by signaling directly to tip cells to regulate the expression of VEGF receptor 3 (VEGFR3). VEGFR3 has a crucial role in mediating the growth of lymphatic vessels, but it is also expressed in endothelial tip cells where it promotes angiogenesis. Indeed, a recent study has shown that disruption of VEGFR3 function in endothelial tip cells using monoclonal antibodies blocks vascular sprouting (Tammela et al., 2008) . Benedito et al. show that VEGFR3 expression in tip cells is decreased when Jag1 is deleted, providing a mechanistic explanation for why these tip cells could have an impaired sprouting response. Thus, one could envision that, just as Dll4-Notch signaling downregulates expression of the VEGF receptor in stalk cells to inhibit vessel growth, Jag1-Notch signaling could upregulate VEGFR3 expression in tip cells to promote vessel growth.
A key question arising from this work is how Jag1 and Fringe family members are themselves regulated in endothelial cells. Jag1 expression can be induced in vitro by inflammatory factors such as tumor necrosis factor α, which could provide a means for integrating signals from the local microenvironment to promote new vessel growth (Sainson et al., 2008) . Evidence from the study of Benedito et al. suggests that Fringe is not expressed uniformly in sprouting vessels but is found in subsets of stalk and tip cells. Given the crucial roles that Fringe members could play in regulating angiogenesis, understanding the upstream factors that control their expression will be essential to further unraveling their function. Lastly, Jag1 clearly plays additional roles during angiogenesis beyond those in tip and stalk cell selection, and it also functions in tissues other than blood vessels (Hofmann and Iruela-Arispe, 2007) . In humans, for example, haploinsufficiency of Jag1 causes Alagille Syndrome, which is characterized by abnormalities in the cardiovascular system, liver, eye, and skeleton (Gridley, 2003) . The ability to selectively delete Jag1 in different tissues and at different developmental stages in model organisms should allow more detailed investigation of the pathogenesis of this disease. Xue, Y., Gao, X., Lindsell, C.E., Norton, C.R., Chang, B., Hicks, C., Gendron-Maguire, M., Rand, E.B., Weinmaster, G., and Gridley, T. (1999). Hum. Mol. Genet. 8, [723] [724] [725] [726] [727] [728] [729] [730] MicroRNAs (miRNAs) play fundamental roles in the regulation of gene expression by pairing via partial Watson Crick interactions with complementary sequences within the 3′ untranslated regions (UTRs) of targeted transcripts (Bartel and Chen, 2004; Bartel, 2009 The importance of miRNAs in finetuning gene expression is highlighted by the demonstration that changes in the abundance of a single miRNA can affect the levels of expression of hundreds of different proteins (Baek et al., 2008; Selbach et al., 2008) . Thus, it is not surprising that a single dysregulated miRNA can push cells into a transformed state. In prior work, Mendell and colleagues have demonstrated that MYC-induced liver tumors in mice result in concomitant downregulation of a number of miRNAs, including miR-15a/16, miR-26a, miR34a, miR-150, and miR-195 (Chang et al., 2008 ). In the current study by Mendell and colleagues (Kota et al., 2009) , the miRNA whose expression is most perturbed in the MYC-induced hepatocarinoma is miR-26a. The authors show that miR-26a regulates the expression of the cyclins D2 and E2 and induces a G1 arrest of human liver cancer cells. Hence, reduced expression of this miRNA is likely to perturb the normal cell-cycle control of hepatocytes.
These investigators asked whether or not forced expression of miR-26a impacts the proliferation of transformed hepatocytes. To test this possibility, they first ectopically expressed miR-26a in a human hepatocellular carcinoma cell line (HepG2 cells) using a murine retroviral vector to transduce the miRNA encoding gene. They then carried out analyses using flow cytometry to determine if forced expression of miR-26a affects the cell cycle of the HepG2 cells relative to an empty vector or forced expression of an irrelevant miRNA. They observe that forced expression of miR-26a, but not the control constructs, results in increased numbers of cells in the G1 stage of the cell cycle and fewer cells in the proliferative S phase. Given this biological effect of miR-26a expression they systematically examined the levels of miR-26a in paired biopsies from normal human liver tissue versus human liver cancer samples. These studies revealed a consistent reduction in the levels of this miRNA in the cancer cells versus normal cells in 7 out of 8 samples tested.
To further investigate the therapeutic potential of miR-26a for hepatocarcinoma, Kota et al. take advantage of a mouse model of hepatocarcinoma in which expression of human MYC is induced by tetracycline. Mice harboring the inducible human MYC transgene develop hepatic cancer following the administration of the tetracycline analog doxycycline. Importantly, MYC does not harbor a miR-26a complementary site in its 3′ UTR, thus eliminating this message as a potential target for miR-26a. The next problem that confronted the investigators was to deliver a miR-26a construct into hepatocytes in vivo. The solution is provided by an adenoassociated virus (AAV) vector, which is highly efficient at transducing hepatocytes in vivo (Figure 1) . Kota et al. placed the miR-26a pre-miRNA in an intron associated with the elongation factor 1 alpha (EF1α) transcription unit, which in turn was fused to an enhanced green fluorescent (EGFP) reporter. Transduced cells can then be monitored by the expression of green fluorescence. The AAV vectors harboring the miR-26a-EGFP transcription unit as well as control vectors are packaged using the AAV8 envelope. This envelope is not known to be associated with human AAV infections, so immunologic memory should not be a problem for using this vector clinically. This is an important point given that the use of AAV2 for in vivo therapy is limited by early immunologic memory of AAV infections (Mingozzi et al., 2007) .
The critical experiment involves the use of this vector to transduce cells in the mouse model of liver cancer. At a critical time following tumor induction, doxycycline is withdrawn and the AAV constructs are delivered by intravenous injection. The majority of this vector localizes to the liver and transduces upwards of 90% of the hepatocytes. The results from these experiments show that 6 out of 10 mice treated with the control vector lacking the miR-26a construct developed liver cancer. In contrast, 8 out of 10 animals treated with the miR-26a construct did not develop disease, and the 2 animals with disease showed lower transduction efficiency of the vector. Animals transduced with the miR-26a construct exhibit apoptosis in the cancer cells, but remarkably the miRNA does not induce apoptosis in nonmalignant hepatocytes.
Taken together, the results are quite remarkable. First, the tumor regression suggests that this miRNA potently regulates cellular proliferation. Nonmalignant hepatocytes are not affected by the ectopic expression of this miRNA, consistent with its high level of expression in normal hepatocytes. The administration of miR-26a by an AAV vector is a key component of this study. The many new serotypes of AAV now available should figure 1. miR-26a Triggers cell-cycle Arrest Adeno-associated viruses (AAV) exist as episomal DNA in the nucleus of cells. A primary miR-26a transcript expressed by the viral vector is processed by Drosha/DGCR8 and is exported to cytoplasm where the pre-miRNA is further processed by Dicer/TRBP. The guide strand is selected for entry into the RNA-induced silencing complex (RISC). The miR-26a guide strands pairs with sequences in the 3′ untranslated regions (UTRs) of target transcripts encoding the cyclins D2 and E2, thereby reducing their expression. This results in the arrest of cells in G1 and inhibits proliferation of hepatocarcinoma cells.
expand the potential clinical applications of this vector. Most importantly, this work convincingly demonstrates that ectopic expression of a single miRNA can markedly impact a disease, in this case hepatic cancer. AAV vectors can be produced in large quantities making it highly suitable as a gene therapy vector. Given that AAV vectors do not integrate into the host genome, they will eventually be eliminated, thereby minimizing the potential of vector-mediated toxicities. What is truly exciting about this study is the strong correlation between miR-26a expression and suppression of hepatic cancer. Restoring miR-26a levels in hepatic cancer cells via transduction with AAV vectors is clearly a path to the clinic that will be exploited given the high prevalence of liver cancer worldwide. The use of a natural miRNA to suppress cell proliferation is exciting and hopefully will lead to a new therapeutic strategy for the treatment of liver cancer.
Successful thieves select targets carefully, knowing that a well-guarded establishment is unlikely to surrender the loot. Oncogenic insults are like thieves in this regard, as their effect is highly dependent on cell type. Their mission is more likely to succeed in a cell where the defenses, such as death, terminal differentiation, senescence, or sensitivity to immune surveillance, are weaker. The last few decades have exposed most of the culprits, a scurrilous cast of activated oncogenes and inactivated tumor suppressors, but the cell-specific weaknesses-the inside crew-that allow them to flourish are more mysterious. Now, David Cobrinik and colleagues redress this balance for the childhood ocular cancer, retinoblastoma (Xu et al., 2009 ). This tumor is initiated by inactivation of both copies of retinoblastoma 1 (RB1) and helped along by subsequent genetic events ( Figure 1A ) (Corson and Gallie, 2007) . Xu et al. now expose a quartet of insiders that help these oncogenic events to take hold: N-Myc, MDM2, and the nuclear receptors RXRγ and THRβ2 ( Figure 1B) . Although their presence is essential for tumorigenesis, they are not altered by any genetic, epigenetic, or posttranscriptional events typically associated with oncogene activation.
To expose retinoblastoma's collaborators, the authors first defined the predominant cell type in retinoblastoma. Prior studies generated conflicting conclusions, failing to distinguish normal versus tumor cells. This issue is elegantly resolved by Xu et al., who in one approach follow RB protein to mark normal cells, and in an even better strategy select tumors with a homozygous RB1 deletion and used fluorescent in situ hybridization to distinguish null tumor from normal cells. Colabeling reveals that most RB1-deficient tumor cells resemble cone photoreceptors, the cells that allow us to see color. Markers present include the retinoic acid-activated nuclear receptor RXRγ and the homeodomain protein CRX (which are also expressed in some other retinal neurons) as well as the cone-specific thyroid hormone-activated nuclear receptor, THRβ2, and two opsins. Humans have three types of cones with distinct opsins that detect blue (short wave, S), green (medium wave, M), and red (long wave, L) light. Xu et al. show that retinoblastoma is replete with markers of M/L cones. This fits well with the presence of THRβ2, which blocks S and promotes L/M cones (Ng et al., 2001 ).
